ABBV vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABBV and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
ABBV is a standard domestic listing, while SNY trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | ABBV | SNY |
|---|---|---|
| Company Name | AbbVie Inc. | Sanofi |
| Country | United States | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 406.64 billion USD | 124.01 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | January 2, 2013 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of ABBV and SNY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABBV | SNY |
|---|---|---|
| 5-Day Price Return | -0.58% | 10.88% |
| 13-Week Price Return | 22.68% | 5.29% |
| 26-Week Price Return | 11.60% | -13.55% |
| 52-Week Price Return | 17.77% | -14.20% |
| Month-to-Date Return | -0.58% | 10.50% |
| Year-to-Date Return | 29.54% | -7.40% |
| 10-Day Avg. Volume | 7.35M | 2.31M |
| 3-Month Avg. Volume | 5.73M | 1.97M |
| 3-Month Volatility | 24.02% | 32.96% |
| Beta | 0.36 | 1.05 |
Profitability
Return on Equity (TTM)
ABBV
95.59%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
In the upper quartile for the Biotechnology industry, ABBV’s Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SNY
14.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
SNY’s Return on Equity of 14.92% is on par with the norm for the Pharmaceuticals industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
ABBV
6.45%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.
SNY
20.51%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
A Net Profit Margin of 20.51% places SNY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ABBV
18.80%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.
SNY
19.08%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
SNY’s Operating Profit Margin of 19.08% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | ABBV | SNY |
|---|---|---|
| Return on Equity (TTM) | 95.59% | 14.92% |
| Return on Assets (TTM) | 2.73% | 8.49% |
| Net Profit Margin (TTM) | 6.45% | 20.51% |
| Operating Profit Margin (TTM) | 18.80% | 19.08% |
| Gross Profit Margin (TTM) | 70.93% | 71.85% |
Financial Strength
Current Ratio (MRQ)
ABBV
0.74
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
ABBV’s Current Ratio of 0.74 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
SNY
1.27
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
SNY’s Current Ratio of 1.27 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
ABBV
49.22
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
SNY
0.32
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
SNY’s Debt-to-Equity Ratio of 0.32 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
ABBV
2.70
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
SNY
22.06
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
SNY’s Interest Coverage Ratio of 22.06 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ABBV | SNY |
|---|---|---|
| Current Ratio (MRQ) | 0.74 | 1.27 |
| Quick Ratio (MRQ) | 0.48 | 0.94 |
| Debt-to-Equity Ratio (MRQ) | 49.22 | 0.32 |
| Interest Coverage Ratio (TTM) | 2.70 | 22.06 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABBV
2.74%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ABBV’s Dividend Yield of 2.74% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
SNY
4.55%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.55%, SNY offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
ABBV
226.84%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
SNY
52.56%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 52.56% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | ABBV | SNY |
|---|---|---|
| Dividend Yield (TTM) | 2.74% | 4.55% |
| Dividend Payout Ratio (TTM) | 226.84% | 52.56% |
Valuation
Price-to-Earnings Ratio (TTM)
ABBV
109.81
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
At 109.81, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
SNY
9.60
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
In the lower quartile for the Pharmaceuticals industry, SNY’s P/E Ratio of 9.60 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Price-to-Sales Ratio (TTM)
ABBV
7.08
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
ABBV’s P/S Ratio of 7.08 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
SNY
1.97
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
SNY’s P/S Ratio of 1.97 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ABBV
261.01
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
SNY
1.44
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
SNY’s P/B Ratio of 1.44 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | ABBV | SNY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 109.81 | 9.60 |
| Price-to-Sales Ratio (TTM) | 7.08 | 1.97 |
| Price-to-Book Ratio (MRQ) | 261.01 | 1.44 |
| Price-to-Free Cash Flow Ratio (TTM) | 22.66 | 10.51 |